Shanghai Haohai Biological Technology Co., Ltd.

SHSE:688366 Stock Report

Market Cap: CN¥12.9b

Shanghai Haohai Biological Technology Past Earnings Performance

Past criteria checks 5/6

Shanghai Haohai Biological Technology has been growing earnings at an average annual rate of 5.3%, while the Biotechs industry saw earnings growing at 7.6% annually. Revenues have been growing at an average rate of 15.8% per year. Shanghai Haohai Biological Technology's return on equity is 6.7%, and it has net margins of 15.7%.

Key information

5.3%

Earnings growth rate

5.1%

EPS growth rate

Biotechs Industry Growth11.3%
Revenue growth rate15.8%
Return on equity6.7%
Net Margin15.7%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Shanghai Haohai Biological Technology makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SHSE:688366 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 242,7474301,200254
30 Jun 242,7464461,210244
31 Mar 242,6894321,209231
31 Dec 232,6544161,223220
30 Sep 232,5303461,197215
30 Jun 232,4873151,179207
31 Mar 232,2632261,120197
31 Dec 222,1301801,088182
30 Sep 222,0632031,132175
30 Jun 221,8611921,065171
31 Mar 221,805272982169
31 Dec 211,750352898168
30 Sep 211,702428759156
30 Jun 211,674434733143
31 Mar 211,594370793135
31 Dec 201,324230772126
30 Sep 201,343232854121
30 Jun 201,306216859121
31 Mar 201,437279831120
31 Dec 191,595371813116
30 Sep 191,537353759108
30 Jun 191,570386732108
31 Mar 191,478375699100
31 Dec 181,54641573795
30 Sep 181,52341171589
30 Jun 181,50140869283
31 Mar 181,42339065080
31 Dec 171,34537260976
30 Sep 171,21435155567
30 Jun 171,08332950259
31 Mar 1796731744053
31 Dec 1685130537847
30 Sep 1678729535844
30 Jun 1672428433740
31 Mar 1669427931938
31 Dec 1566427330135
30 Sep 1563025827832
30 Jun 1559724325528
31 Mar 1555621324627
31 Dec 1451618423626
30 Sep 1448216922127
30 Jun 1444915420628
31 Mar 1442514819226
31 Dec 1340114217824

Quality Earnings: 688366 has high quality earnings.

Growing Profit Margin: 688366's current net profit margins (15.7%) are higher than last year (13.7%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 688366's earnings have grown by 5.3% per year over the past 5 years.

Accelerating Growth: 688366's earnings growth over the past year (24.5%) exceeds its 5-year average (5.3% per year).

Earnings vs Industry: 688366 earnings growth over the past year (24.5%) exceeded the Biotechs industry 1.3%.

Return on Equity

High ROE: 688366's Return on Equity (6.7%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 07:18
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shanghai Haohai Biological Technology Co., Ltd. is covered by 17 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jingwei QiChina Merchants Securities Co. Ltd.
Xiaofang XuCitic Securities Co., Ltd.
Eva ZhaoCitigroup Inc